RougeTx launches with $58M to tackle rare bleeding disorder
Dutch biotech RougeTx has launched with a $58 million (€52 million) series A to take its lead drug RTX-001 toward first-in-human testing in hereditary hemorrhagic telangiectasia (HHT). The round was co-led by BioGeneration Ventures, Angelini Ventures and Kurma Partners, with the European Investment Bank (EIB) participating through Angelini's Aurea co-investment vehicle.
Why it matters: There are currently no therapies approved specifically for HHT. The inherited disease causes abnormal connections between arteries and veins – arteriovenous malformations (AVMs) – which can result in recurrent nose and gastrointestinal bleeding, anemia, and complications in the lungs, liver, and brain.
How it works: RougeTx is targeting pericytes, cells that wrap around small blood vessels and help maintain their structure and stability. In HHT, defective interactions between pericytes and the endothelial cells lining blood vessels are thought to contribute to the formation of fragile vessels and vascular malformations.
- RTX-001 is a small molecule designed to restore the attachment of pericytes to blood vessels, to stabilise them before bleeding occurs. RougeTx has not disclosed the drug’s molecular target in its launch announcement.
Backstory: RougeTx co-founder Franck Lebrin was lead author of a 2010 Nature Medicine study showing that thalidomide reduced nosebleeds in a small group of people with HHT. In an HHT mouse model, the drug increased the recruitment of pericytes and improved vessel stability.
The bigger picture: Alongside pomalidomide, systemic bevacizumab is used off-label in some patients, while the oral kinase inhibitor pazopanib has also been studied for HHT-related bleeding. But these approaches remain unapproved specifically for the disease. RougeTx is positioning RTX-001 as a treatment that could act directly on the vascular instability behind HHT.
Also notable: The financing is the fourth investment in less than a year under a €150 million partnership between Angelini Ventures and the EIB. Launched in December 2025, the initiative combines €75 million from each partner to co-invest in European biotech, medtech and digital health companies.
What to watch: The Series A will fund RTX-001 toward its first clinical trial, but RougeTx has not disclosed when it expects to begin dosing patients. The company also plans to use its platform to identify additional small-molecule programmes for diseases associated with vascular instability.
